RecruitingPhase 1NCT06922539

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

Sponsor

SciTech Development, Inc.

Enrollment

44 participants

Start Date

Dec 11, 2025

Study Type

INTERVENTIONAL

Conditions

Small Cell Lung Cancer

Summary

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called ST-001 nanoFenretinide for people with small cell lung cancer (SCLC) that has returned or stopped responding to prior treatment. NanoFenretinide is an experimental form of a synthetic vitamin A compound that may help kill cancer cells. **You may be eligible if...** - You have small cell lung cancer of any stage that is incurable - Your cancer has come back or is no longer responding to treatment - You have had prior platinum-based chemotherapy or radiation therapy - At least 4 weeks have passed since your last treatment, and you have recovered from its side effects - Your ECOG performance status is 0 or 1 (you are functional and relatively active) - Your life expectancy is greater than 6 months **You may NOT be eligible if...** - Your cancer has never been treated before - You have not recovered from side effects of prior treatment - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.